安罗替尼联合经导管动脉化疗栓塞术治疗晚期原发性肝癌的临床疗效  

Clinical Efficacy of Anlotinib in Combination with TACE in the Treatment of Advanced Primary Hepatic Carcinoma

作　　者：刘琳 张凯 周丽娟 LIU Lin;ZHANG Kai;ZHOU Li-juan(Department of Pharmacy,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450007,China;Translational Medicine Center,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450007,China)

机构地区：[1]郑州大学附属郑州中心医院药学部,郑州450007 [2]郑州大学附属郑州中心医院转化医学中心,郑州450007

出　　处：《中国合理用药探索》2023年第2期59-65,共7页Chinese Journal of Rational Drug Use

基　　金：河南省医学教育研究项目(Wjlx2021410)。

摘　　要：目的:探讨安罗替尼与经导管动脉化疗栓塞术(TACE)治疗晚期原发性肝癌(PHC)的临床疗效和安全性。方法:选取2020年1月~2022年1月某院收治的80例晚期PHC患者作为研究对象,采用随机数字表法分为对照组和联合组,每组40例。对照组予以单纯TACE治疗,联合组在TACE基础上加用盐酸安罗替尼胶囊。比较两组疾病控制率(DCR)、不良反应发生情况。分别于治疗前和术后1个月采用Karnofsky评分评估患者生活质量,并检测血清甲胎蛋白(AFP)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)及胰岛素样生长因子-2(IGF-2)水平。结果:术后1个月,联合组Karnofsky评分高于对照组(P<0.05);联合组血清AFP、MMP-9、VEGF和IGF-2水平低于对照组(P<0.05);联合组DCR(87.50%)高于对照组(67.50%,P<0.05);两组不良反应发生情况比较无统计学差异(P>0.05)。联合组出现了手足综合征(12.50%)、高血压(7.50%)、蛋白尿(12.50%)等不良反应,均为1~2级,未发生3级及以上不良反应。结论:安罗替尼联合TACE治疗晚期PHC可下调血清肿瘤生长相关因子水平,提高临床疗效,且安全性良好。Objective:To investigate the clinical efficacy and safety of anlotinib in combination with transcatheter arterial chemoembolization(TACE)in treating advanced primary hepatic carcinoma(PHC).Methods:From January 2020 to January 2022,80 patients with advanced PHC were assgined into control group and combination group by random number table,with 40 cases in each group.The control group was treated with TACE only,and the combination group was treated with anlotinib hydrochloride capsules in combination with TACE.The disease control rate(DCR)and adverse reactions were compared between the two groups.The quality of life of patients was evaluated by Karnofsky score,and the levels of serum alphafetoprotein(AFP),matrix metalloproteinase-9(MMP-9),vascular endothelial growth factor(VEGF)and insulin-like growth factor-2(IGF-2)were measured before treatment and one month after treatment.Results:One month after treatment,the Karnofsky score in the combination group was significantly higher than that of control group(P<0.05),and the levels of serum AFP,MMP-9,VEGF and IGF-2 were lower than those of control group(P<0.05).The DCR in the combination group was 87.50%,which was significantly higher than 67.50%of the control group(P<0.05).No significant difference in the incidence of adverse reactions between the two groups was observed(P>0.05).Hand-foot syndrome(12.50%),hypertension(7.50%),proteinuria(12.50%)and other adverse reactions occurred in the combination group,all of which were grade 1~2,and no grade 3 and above adverse reactions occurred.Conclusion:For advanced PHC,TACE in combination with anlotinib can down-regulate the levels of serum tumor growth factor,improve the clinical efficacy with favorable safety.

关 键 词：原发性肝癌 肝动脉化疗栓塞 安罗替尼 肿瘤生长因子 疗效 

分 类 号：R735.7[医药卫生—肿瘤]